Clinicopathological features of patients with solid papillary carcinoma of the breast: An analysis of 144 cases

Abstract

Objective To investigate the clinicopathological features and prognosis of patients with solid papillary carcinoma (SPC) of the breast. Methods A retrospective analysis was performed for the clinical data of 144 patients with SPC of the breast who were admitted to our hospital from August 2017 to May 2023, especially the immunohistochemistry results of related pathological indicators in pathological sections, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), Ki-67, p53, Syn, cytokeratin 5/6 (CK5/6), and p63. Results Among the 144 patients, there were 142 female patients, with a mean age of (64.6±10.7) years and a median tumor largest diameter of 8.0 (4.3,19.0) cm. There were 62 patients with in situ SPC, 82 with invasive carcinoma, and 3 with ipsilateral axillary lymph node metastasis. Immunohistochemistry was performed for all 144 patients, with the positive expression of ER and the negative expression of HER-2 in all patients, among whom 130 patients (92.2%) had a Ki-67 positivity rate of ≤20% (presenting with the Luminal A immunophenotype). Of all patients, 29 underwent breast-sparing mastectomy for breast cancer, 94 underwent total mastectomy, 21 underwent modified radical mastectomy for breast cancer, and 98 underwent postoperative adjuvant endocrine therapy. The follow-up time was 31 (16,58) months for these patients, and no recurrence or metastasis was observed. Conclusion SPC of the breast is a type of low-grade malignant tumor with special morphological features, and it often presents with the Luminal A immunophenotype. Surgery and endocrine therapy are the main treatment methods based on carcinoma in situ or corresponding invasive carcinoma, and patients tend to have a good prognosis.

Keywords

• carcinoma, papillary|breast neoplasms|immunohistochemistry|prognosis